Beyond the Neuron: TDP-43 and the Challenge of Pre-Analytical Quality in Platelet Biomarker Development
- 1Department of Medical Laboratory Sciences, College of Health Sciences, Debre Tabor University, Debre Tabor P.O. Box 272, Ethiopia
- 2Molecular Pathology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), 34149 Trieste, Italy
Abstract
TAR DNA-binding protein 43 (TDP-43) is the primary pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Yet, despite two decades of intensive research, a reliable peripheral TDP-43 biomarker remains elusive. Recognizing platelets as a major blood reservoir of TDP-43 opens new diagnostic avenues but may also reveal potential vulnerabilities. In this narrative review, we first trace the evolving understanding of TDP-43 from a nuclear RNA-binding protein to a molecule whose functions and disease-associated alterations extend beyond the neuron. We then examine recent breakthroughs demonstrating that TDP-43 function is shaped by its cellular environment and how it may be uniquely concentrated in platelets. Next, we argue that pre-analytical variables, such as hemolysis, clotting, cold-chain failures, and biobank protocols, are not mere “noise” but potential confounders that distort molecular integrity and should be taken into account. Finally, we discuss the biological and methodological uncertainties surrounding platelet TDP-43 and highlight how standardized handling and systematic pre-analytical reporting can improve reproducibility and support future biomarker validation. More broadly, the methodological standards outlined in this review may extend beyond TDP-43 to other disease-related proteins that are present in platelets and similarly sensitive to pre-analytical variability.
Related
- Case Report: Sporadic Creutzfeldt–Jakob disease initially misdiagnosed as ischemic stroke: a diagnostic challenge and biomarker-based clarification
- Development of CRISPR/Cas13-based analytical tools to study RNA–protein interactions
- Large Language Model Framework for Structured Biomarker Extraction and Triple-Negative Breast Cancer Identification From Pathology Reports: Development and Evaluation Study.
- The heart-liver axis controls platelet turnover by hepatic STAT3 phosphorylation and TPO regulation after acute myocardial infarction
- Inhibition of macrophage neuraminidase 1 protects against immune thrombocytopenia by limiting platelet clearance
BibTeX
@article{malkamu2026beyond,
title = {{Beyond the Neuron: TDP-43 and the Challenge of Pre-Analytical Quality in Platelet Biomarker Development}},
author = {Birhanemaskal Malkamu and Emanuele Buratti and Sara Cappelli},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219691},
url = {https://www.mdpi.com/1422-0067/27/21/9691},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Beyond the Neuron: TDP-43 and the Challenge of Pre-Analytical Quality in Platelet Biomarker Development
AU - Birhanemaskal Malkamu
AU - Emanuele Buratti
AU - Sara Cappelli
PY - 2026
DA - 2026/10/29
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219691
UR - https://www.mdpi.com/1422-0067/27/21/9691
AB - TAR DNA-binding protein 43 (TDP-43) is the primary pathological hallmark of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Yet, despite two decades of intensive research, a reliable peripheral TDP-43 biomarker remains elusive. Recognizing platelets as a major blood reservoir of TDP-43 opens new diagnostic avenues but may also reveal potential vulnerabilities. In this narrative review, we first trace the evolving understanding of TDP-43 from a nuclear RNA-binding protein to a molecule whose functions and disease-associated alterations extend beyond the neuron. We then examine recent breakthroughs demonstrating that TDP-43 function is shaped by its cellular environment and how it may be uniquely concentrated in platelets. Next, we argue that pre-analytical variables, such as hemolysis, clotting, cold-chain failures, and biobank protocols, are not mere “noise” but potential confounders that distort molecular integrity and should be taken into account. Finally, we discuss the biological and methodological uncertainties surrounding platelet TDP-43 and highlight how standardized handling and systematic pre-analytical reporting can improve reproducibility and support future biomarker validation. More broadly, the methodological standards outlined in this review may extend beyond TDP-43 to other disease-related proteins that are present in platelets and similarly sensitive to pre-analytical variability.
SN - 1422-0067
ER -